131 results
Page 2 of 7
10-K
EX-10.51
t9bqg dxl
12 Feb 18
Annual report
12:00am
10-K
1fe cmaw5
12 Feb 18
Annual report
12:00am
10-K
EX-10.32
et49ycmpgv1 gmb
12 Feb 18
Annual report
12:00am
10-K
EX-10.27
dmd 7akjia29zdi90gqe
12 Feb 18
Annual report
12:00am
10-K
EX-10.21
lwdhd
12 Feb 18
Annual report
12:00am
10-K
EX-10.31
m6j9coewgavmmym1bqf
12 Feb 18
Annual report
12:00am
10-K
EX-10.23
11s2mt8
12 Feb 18
Annual report
12:00am
10-K
EX-10.39
klnc0vm0vfc qrgd
12 Feb 18
Annual report
12:00am
10-K
EX-10.44
j4j7ma234ucijiuloy
12 Feb 18
Annual report
12:00am
10-K
EX-10.22
ftcded1j3fcy5bz6
12 Feb 18
Annual report
12:00am
10-K
EX-10.62
c51tv290m
12 Feb 18
Annual report
12:00am
6-K
EX-99.1
oihzoodmwy5htp6 92z9
7 Jun 17
Live Filing
12:00am
6-K
EX-99.1
84286c2ofvd6u
12 Apr 16
Teva to Present Data Highlighting Company’s Pipeline in Neurological Disorders at 68th AAN Annual Meeting
12:00am
6-K
EX-99.1
q3ttgozy
30 Sep 15
IMPORTANT NEW DATA FROM TEVA’S TEV-48125 PHASE 2b MIGRAINE PROGRAM PUBLISHED INLANCET NEUROLOGYIN BACK-TO-BACK ARTICLES
12:00am
6-K
EX-99.1
ievrn15a71 8juqt0epm
23 Mar 15
Live Filing
12:00am
6-K
EX-99.1
6ux3auotzzz0za1gir
24 Feb 15
TEVA ANNOUNCES POSITIVE RESULTS FOR TEV-48125 IN PHASE IIb CHRONIC MIGRAINE STUDY MEETING PRIMARY AND SECONDARY ENDPOINTS
12:00am
6-K
EX-99.1
mo5pi
12 Sep 14
Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting
12:00am